Welcome to our dedicated page for Dbv Technologies S A news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on Dbv Technologies S A stock.
DBV Technologies SA (DBVT) is a clinical-stage biopharmaceutical leader advancing epicutaneous immunotherapy (EPIT) through its innovative Viaskin platform, targeting food allergies with non-invasive precision. This page aggregates all essential updates on the company’s clinical progress, regulatory milestones, and strategic initiatives.
Investors and stakeholders gain centralized access to critical developments including phase trial results, FDA/EMA interactions, and partnership announcements. Each update is curated to provide actionable insights into DBVT’s pioneering work in allergy treatment while maintaining rigorous scientific accuracy.
Key coverage areas include Viaskin efficacy data, patent developments, and manufacturing scalability updates. The resource is designed to help users track the company’s progress from clinical research to potential commercialization without requiring cross-platform monitoring.
Bookmark this page for streamlined tracking of DBV Technologies’ advancements in redefining food allergy management through its unique skin-based immunotherapy approach.
DBV Technologies has released its Half-Year Report for the liquidity contract with ODDO BHF, detailing financial transactions and asset management as of June 30, 2022. The liquidity account holds 106,287 shares valued at €430,854.35. Since the contract's inception in July 2018, resources have slightly decreased from 41,159 shares and €432,367.25 initially. In the first half of 2022, 706 purchases and 869 sales were made, with total volumes of €1,056,560.18 for purchases and €1,311,871.05 for sales.
DBVT announced the total number of shares and voting rights as of June 30, 2022. The company has 94,022,679 shares and 94,022,679 voting rights in total, with a net of 92,916,392 voting rights after accounting for shares without voting rights. This information complies with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers.
The stock is traded on the NYSE Euronext Paris under ISIN code FR 0010417345.
DBV Technologies announced its participation in the EAACI 2022 Congress from July 1-3 in Prague, Czech Republic. The company will present key data on the economic burden of peanut allergies in children aged 4-11 in Europe and showcase a novel Basophil Activation Test (BAT) to predict peanut challenge outcomes. Additionally, DBV will host a symposium on food allergies and exhibit its Viaskin™ technology, aimed at treating peanut allergies. This innovative approach aims to reduce allergic reactions in peanut-allergic children.
DBV Technologies, a clinical-stage biopharmaceutical company, will present at the JMP Securities Life Sciences Conference in New York on June 16, 2022, at 12:00 p.m. ET. CEO Daniel Tassé and CMO Dr. Pharis Mohideen will participate in a fireside chat. Investors can access a live webcast of the event on the company's website, with a replay available afterward. DBV Technologies is focused on developing Viaskin™, an innovative platform for non-invasive immunotherapy targeting food allergies, including ongoing trials for Viaskin Peanut.
DBV Technologies announced a $194 million private placement financing on June 9, 2022, aimed at strengthening its financial position. The deal involves selling 32,855,669 ordinary shares at €3.00 each and pre-funded warrants at €2.90, with total gross proceeds estimated at approximately $194 million before expenses. Major investors include Braidwell LP, Baker Bros. Advisors LP, and Venrock Healthcare Capital Partners, among others. The closing of the financing is anticipated on June 13, 2022, subject to customary conditions.
DBV Technologies announced positive topline results from its Phase 3 EPITOPE trial evaluating Viaskin Peanut for peanut-allergic toddlers aged 1 to 3 years. The trial met its primary endpoint, with 67% of subjects in the treatment group achieving significant response criteria after 12 months, compared to 33.5% in the placebo group. Safety results were consistent with prior studies in older children, showing high compliance and a low discontinuation rate due to adverse events. DBV aims to analyze data for regulatory pathways, addressing a critical unmet need in this age group.
DBVT reported its total shares and voting rights as of April 30, 2022. The total number of shares stood at 55,095,537, while the total gross voting rights were also 55,095,537. After accounting for shares without voting rights, the total net voting rights amounted to 54,920,329. This information is compliant with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers.
DBV Technologies held its Ordinary and Extraordinary General Meeting on May 12, 2022, where shareholders approved all proposed resolutions from the Board of Directors. The meeting, chaired by Michel de Rosen, confirmed the company's ongoing commitment to its strategic initiatives.
DBV Technologies is advancing Viaskin™, a proprietary platform for non-invasive immunotherapy aimed at treating food allergies, including clinical trials for Viaskin Peanut. For more information, visit the investors section of their website.
DBV Technologies has successfully completed the sale of American Depositary Shares (ADSs) raising $15.3 million through its At-The-Market program. The sale involved issuing 12,072,476 new ADSs, equivalent to 6,036,238 ordinary shares, resulting in a dilution of approximately 9.9% to existing shareholders. This capital increase will facilitate the company’s ongoing clinical trials for its Viaskin immunotherapy platform, aiming to enhance treatment options for food allergies. The delivery of new shares is scheduled for May 6, 2022.
DBV Technologies has announced an At-The-Market (ATM) program on Nasdaq, allowing it to raise up to $100 million through the sale of American Depositary Shares (ADS). This program, effective until July 16, 2024, will support the potential approval and launch of Viaskin™ Peanut and advance the development of other products. The plan involves selling up to 16,528,961 ordinary shares, potentially leading to a dilution of around 30%. Jefferies LLC will act as the sales agent, and the proceeds will also cover general corporate purposes.
FAQ
What is the current stock price of Dbv Technologies S A (DBVT)?
What is the market cap of Dbv Technologies S A (DBVT)?
